| Document |
Document Title |
|
WO/2020/210485A1 |
Disclosed are processes for preparing α-carboxamide pyrrolidine derivatives, in particular (2S,5R)-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carbo
xamide, and intermediates for use in said processes along with processes for prepari...
|
|
WO/2020/210486A1 |
The disclosure provides processes for preparing α-carboxamide pyrrolidine derivatives, in particular (2S, 5R)-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carboxami
de, as well as intermediates for use in said processes.
|
|
WO/2020/209205A1 |
The present invention addresses the problem of providing a compound having high photobase generation efficiency. This carbamoyloxime compound is represented by general formula (I) (in the formula, A represents an aromatic ring-containing...
|
|
WO/2020/202072A1 |
The present invention relates to a compound of Formula la, lb and Ic, (Formula Ia) a pharmaceutical composition comprising the same and their use in the treatment or prevention of pathological conditions associated to depolarizing GABAer...
|
|
WO/2020/203610A1 |
Provided is a medicinal drug for treating or preventing rheumatoid arthritis. As a medicinal drug for treating or preventing rheumatoid arthritis, the present invention uses, as an active ingredient, a compound that has an effect of bloc...
|
|
WO/2020/202183A1 |
The present invention provides an improved process for the preparation Upadacitinib by using novel intermediates. The present invention also provides processes for the preparation of novel intermediates of Upadacitinib.
|
|
WO/2020/199683A1 |
A nitrogen heterocycle substituted sulfonylbenzamide derivative, a preparation method therefor and use thereof in medicine are involved. Specifically, a compound of formula (I) or a pharmaceutically acceptable salt, a stereoisomer, a sol...
|
|
WO/2020/202944A1 |
Provided is an active light-sensitive or radiation-sensitive resin composition, etc., that is capable of forming a pattern having an extremely excellent rectangular shape in the cross-section thereof, when forming a pattern having an ext...
|
|
WO/2020/205934A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
|
WO/2020/205470A1 |
The present disclosure provides compounds and methods for inhibiting or degrading the N-terminal domain of the androgen receptor, as well as methods for treating cancers such as prostate cancer.
|
|
WO/2020/203609A1 |
Provided is a medicinal drug for treating or preventing pruritus. As a medicinal drug for treating or preventing pruritus, the present invention uses, as an active ingredient, a compound that has an effect of blocking the Cav3.2 T-type c...
|
|
WO/2020/198940A1 |
Provided is a crystal form A of 2-(2,5-dioxopyrrolidin-1yl)ethylmethylfumarate. The crystal form has a good light irradiation stability, high-temperature stability and high-humidity stability.
|
|
WO/2020/193419A1 |
The present invention relates to novel compounds, pharmaceutical compositions comprising such compounds and their use for treating, alleviating or preventing diseases or disorders relating to the activity of potassium channels.
|
|
WO/2020/195889A1 |
The purpose of the present invention is to provide a method for producing a pyrrole imidazole poly(amide) compound at a high yield with high reproducibility, by quickly improving the conversion rate in a reaction for forming an amide bon...
|
|
WO/2020/188301A1 |
There is herein provided a compound of formula I or a pharmaceutically acceptable salt thereof, wherein X, R1, R2, R3, ring A, n and y have meanings as provided in the description.
|
|
WO/2020/184670A1 |
The present invention relates to a method for monodeuterated lower alkylating an amine moiety of a compound which contains an amine that is protected by an aralkyl group, wherein a monodeuterated lower alkyl is introduced into the amine ...
|
|
WO/2020/183379A1 |
Present invention relates to novel salts of saroglitazar and certain polymorphic forms of saroglitazar salts. Invention provides process for the preparation of novel salts and polymorphic forms of saroglitazar. Invention also provides no...
|
|
WO/2020/184944A1 |
The present application relates to a technology enabling a specific number of chemical functional groups or cargo moieties to be labeled at specific sites of an antibody. An antibody product having high uniformity can be provided by the ...
|
|
WO/2020/182227A1 |
Disclosed is a preparation method for high purity liraglutide side chain, comprising: using palmitic acid, N-hydroxysuccinimide and N,N'-diisopropylcarbodiimide as reaction starting materials, and sequentially obtaining Palmitoyl-OSu, Pa...
|
|
WO/2020/181688A1 |
The present invention sets forth a preparation method for a drug-linker MC-MMAF used as an antibody-drug conjugate, and an intermediate thereof. The preparation method of the present invention improves the reactivity of an N-terminal, th...
|
|
WO/2020/185830A1 |
The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof: (I) The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.
|
|
WO/2020/180624A1 |
Compounds are provided having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein A, X1, X2, Q, R1, R2 and n are as defined herein. Such compounds function ...
|
|
WO/2020/173016A1 |
The present invention relates to a resorcinol dianisole derivative, wherein the chemical structure of this compound is as represented by the following formula (I). The compound of the present invention can inhibit the binding of programm...
|
|
WO/2020/175035A1 |
Provided is a silyl ether-containing sulfonate salt that contains an anion represented by formula (1) and a cation. (In the formula, R1 to R4 are each independently a C1-4 alkyl group. m is an integer from 1 to 3. n is an integer from 2 ...
|
|
WO/2020/174030A1 |
Acatalyst composition comprising at least one compound with a general formula (I) wherein A is N-R3, R3 is C1-C8 linear or branched, x = 0-6, n and m are each independently 1 to 6, R1 and R2 are each independently C2 -C8 alkyl, and R4 an...
|
|
WO/2020/174086A2 |
The present invention in general relates to the field of bioconjugation. More in particular, the invention relates to novel bioconjugation reactants based on an α,β unsaturated γ- hydroxylactam structure, amongst others allowing a hig...
|
|
WO/2020/176428A1 |
The present disclosure relates generally to therapeutic agents that may be useful as inhibitors of Integrated Stress Response (ISR) pathway. Compounds and compositions detailed herein, such as a pharmaceutical composition containing a co...
|
|
WO/2020/170080A1 |
A hydrofluoroolefin compound is represented by the following general formula (I): where RF1 is a hydrogen atom or CH3, and (iii) RF1 is a linear or branched perfluorinated alkyl group having 1 to 10 carbon atoms and optionally including ...
|
|
WO/2020/169682A1 |
The present invention relates to compounds of the following general formula (I): or a pharmaceutically acceptable salt and/or solvate thereof, their use as a drug, in particular as antibacterial agent, notablyforpreventingand/or treating...
|
|
WO/2020/167706A1 |
The present invention is directed to 5-alkyl pyrrolidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neuro...
|
|
WO/2020/166613A1 |
An agent for eliminating pluripotent stem cells that comprises an antibody-drug conjugate or a salt thereof, said antibody-drug conjugate releasing a compound represented by formula (1-1) [wherein: b represents an integer of 1-5; and Z r...
|
|
WO/2020/167701A1 |
The present invention is directed to pyrrolidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological ...
|
|
WO/2020/161199A1 |
The present invention relates to nitro-vinyl-pyrazole compounds of formula, wherein ring A, RB2 and RB3 are as defined in claim 1, as well as the manufacture of such compounds and their subsequent use in the production of agrochemicals a...
|
|
WO/2020/161148A2 |
The present invention relates to pyrazole derivatives of formula (X) wherein ring A is a pyrazole and substituents RB1, RB2, n, RQ1, RQ2, RQ3, and RQ4 are as defined in claim 1, their manufacture, and their use in the manufacture of agro...
|
|
WO/2020/156359A1 |
Disclosed in the present invention are a quaternary ammonium salt compound and a preparation method therefor and a use thereof, relating to the field of medicinal chemistry. Disclosed in the present invention is the compound shown in for...
|
|
WO/2020/157126A1 |
The present invention relates to a class of novel compounds of general formula (I), their use as medicaments and pharmaceutical compositions comprising them. Specifically, the compounds of the invention are useful as voltage-gated potass...
|
|
WO/2020/156022A1 |
Provided herein are enantioselective organocatalytic methods for preparing chiral tetraaryl methanes.
|
|
WO/2020/160222A2 |
A compound of Formula I or a pharmaceutically acceptable ester, amide, solvate, or salt thereof, or a salt of such an ester or amide or a solvate of such an ester amide or salt, Formula (I) is disclosed. Compositions comprising the compo...
|
|
WO/2020/159167A1 |
The present invention provides a method for recovering amide-based compounds, wherein, before a distillation step for separating and recovering amide-based compounds from waste liquid including amide-based compounds such as N-methyl-2-py...
|
|
WO/2020/158958A1 |
The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexi...
|
|
WO/2020/151687A1 |
Provided is an N-benzyl-N-arylsulfonamide derivative, which is an N-benzyl-N-arylsulfonamide compound represented by a general formula (I), or a pharmaceutically acceptable salt or solvate thereof. The N-benzyl-N-arylsulfonamide derivati...
|
|
WO/2020/116589A9 |
The purpose of the present disclosure is to provide a novel method for producing a fluorovinyl amide compound. The purpose is achieved by means of a method for producing a compound represented by formula (I) [in the formula, Rf is -F or ...
|
|
WO/2020/151252A1 |
Provided is a compound of formula I or II, a stereoisomer, a tautomer, a geometrical isomer, a solvate, an active metabolite, a hydrate, a prodrug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof, and t...
|
|
WO/2020/152361A1 |
The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are usef...
|
|
WO/2020/153774A1 |
The present application pertains to a novel linker for use in bioconjugation, containing two or more electrophilic carbon atoms of a carbonyl group, and a click chemistry functional group and, more specifically, to a linker through which...
|
|
WO/2020/148325A1 |
The present invention relates to amine, carboxamide or thioamide containing compounds which bind to the liver X receptor (LXRα and/or LXRβ) and act preferably as inverse agonists of LXR. The compounds are of formula (I) wherein rings A...
|
|
WO/2020/148787A1 |
The present invention relates to an improved and economical process for enantioselective synthesis and purification of a novel key intermediate of Brivaracetam. Further, the present invention also relates to a process for the preparation...
|
|
WO/2020/143674A1 |
Provided is a compound of formula III, and also provided are its use and method in the synthesis of Brivaracetam APIs. The raw materials involved in the method are cheap and easy to obtain, and can prepare Brivaracetam APIs with high opt...
|
|
WO/2020/145831A1 |
The first object of the invention is the compound of general formula (I) or pharmaceutically acceptable salts thereof. A second object of the invention is the use of compounds described by general formula (I) as active ingredient in phar...
|
|
WO/2020/143198A1 |
Ketamine derivatives and pharmaceutical compositons thereof are disclosed. When administered orally the ketamine derivatives provide increased bioavailability of ketamine in the systemic circulation. The ketamine derivatives can be used ...
|
